Eular 2023

Reade laat ook dit jaar weer zien hoe de behandeling van reumatische aandoeningen verbeterd kan worden. Hieronder zie je welke collega's hun kennis de komende dagen delen.

Woensdag 31 mei

Sprekers:

• Maarten Boers - How to best present your data
• Laura Boekel - Patients with inflammatory rheumatic diseases are NOT at increased risk of long-COVID: data from a large prospective controlled cohort study

Posters:

• Bas Dijkshoorn - Targeting NET formation in early RA patients; a spin-off study from the NORD-STAR

Donderdag 1 juni

Sprekers:

• Ronald van Vollenhoven - AstraZeneca - Anifrolumab in SLE – perspectives from the real world
• Ronald van Vollenhoven - The future perspectives in the treatment of SLE & Sjören's
• Ronald van Vollenhoven - Efficacy and Safety of telitacicept, a novel BLyS/APRIL dual inhibitor, in patients with systemic lupus erythematosus: a phase 3, randomized, placebo-controlled 52-week study
• Carlijn Wagenaar - Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: one-year follow-up of the “Plants for Joints” randomized clinical trial

Posters:

• Bas Dijkshoorn - Targeting NET formation in early RA patients; a spin-off study from the NORD-STAR
• Carlin Wagenaar - Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: one-year follow-up of the “Plants for Joints” randomized clinical trial
• Eva van Geel - The correlation between four adherence measurements methods in patients with rheumatoid arthritis using methotrexate

Vrijdag 2 juni

Sprekers:

• Bas Dijkshoorn - Case 1. Congestive heart disease
• Mike Nurmohamed - Congestive heart failure in RMDs: effects of therapies
• Maarten Steinz / Martin van der Esch - SMR study group (meeting)

Zaterdag 3 juni

Sprekers:

• Ronald van Vollenhoven - Transforming lives: Funding and delivering the future of European research in rheumatology
• Wilfred Peter - Highlights from the HPR Programme